全文获取类型
收费全文 | 80篇 |
免费 | 5篇 |
国内免费 | 7篇 |
专业分类
儿科学 | 1篇 |
妇产科学 | 3篇 |
基础医学 | 11篇 |
口腔科学 | 4篇 |
临床医学 | 16篇 |
内科学 | 17篇 |
特种医学 | 6篇 |
外科学 | 4篇 |
综合类 | 3篇 |
预防医学 | 15篇 |
眼科学 | 4篇 |
药学 | 7篇 |
肿瘤学 | 1篇 |
出版年
2021年 | 1篇 |
2020年 | 2篇 |
2019年 | 2篇 |
2018年 | 3篇 |
2017年 | 2篇 |
2016年 | 1篇 |
2015年 | 1篇 |
2014年 | 1篇 |
2013年 | 10篇 |
2011年 | 3篇 |
2010年 | 4篇 |
2009年 | 8篇 |
2008年 | 2篇 |
2007年 | 7篇 |
2006年 | 1篇 |
2005年 | 5篇 |
2004年 | 4篇 |
2003年 | 1篇 |
2001年 | 1篇 |
1999年 | 1篇 |
1998年 | 6篇 |
1997年 | 3篇 |
1996年 | 2篇 |
1995年 | 3篇 |
1994年 | 1篇 |
1993年 | 3篇 |
1992年 | 1篇 |
1989年 | 2篇 |
1988年 | 4篇 |
1986年 | 2篇 |
1983年 | 1篇 |
1980年 | 1篇 |
1965年 | 1篇 |
1959年 | 1篇 |
1951年 | 1篇 |
排序方式: 共有92条查询结果,搜索用时 15 毫秒
81.
Svensson J Monson JP Vetter T Hansen TK Savine R Kann P Bex M Reincke M Hagen C Beckers A Ilondo MM Zdravkovic M Bengtsson BA Korbonits M;NN Clinical Research Group 《Clinical endocrinology》2003,58(5):572-580
OBJECTIVE: Little is known of the usefulness of GH secretagogues (GHSs) in GH-deficient (GHD) adults. The objective of this study was to determine the number of responders to treatment with NN703 in GHD adults. DESIGN: A multicentre, randomized, double-blind, and placebo-controlled study. PATIENTS: Ninety-seven GHD adults were included. MEASUREMENTS: The GH response before and after 1 week of oral treatment with NN703 (n = 83) or placebo (n = 14) was determined. The first and last dose of NN703 was 3 mg/kg, whereas the dose of NN703 was 1.5 mg/kg/day during the 6 days between the first and last doses. Furthermore, all 97 patients received 1 micro g/kg GH-releasing hormone (GHRH) 3 weeks after the last dose of NN703. RESULTS: Serum GH peak and area under curve (AUC) values after the first NN703 administration were greater than those after placebo administration (P < 0.05). However, after correction for the lower body mass index (BMI) in the NN703 group, this difference lost statistical significance. After 1 week of therapy, GH peak and AUC values were similar following the final doses of NN703 and placebo. Serum peak and AUC values of other anterior pituitary hormones were similar between the NN703 and placebo groups both after the first and last administration of study drug. Nine of the 83 patients (11%) responded with a serum peak GH concentration >or= 5 micro g/l after the first and/or last NN703 administration, whereas no patient responded after placebo administration. Serum IGF-I was unaffected by 1-week NN703 treatment, whereas serum IGFBP-3 was increased (P < 0.05 vs. placebo) also after correction for BMI. Mean serum peak GH concentration after GHRH administration was 2.1 micro g/l (+/-0.3, SEM), which was higher than that after the first NN703 administration (1.32 +/- 0.3, P < 0.05). CONCLUSION: NN703 administration was generally well tolerated. Eleven per cent of the GHD adult patients responded with a peak GH response >or= 5 micro g/l after the first and/or last administration of oral NN703. Although a majority of GHD adults will not respond to NN703, the present results suggest that oral NN703 treatment could be useful in some adult patients with moderately severe GHD. These patients may be identified by a test dose of GHS. 相似文献
82.
83.
A soluble activity from adherent marrow cells cooperates with IL 3 in stimulating growth of pluripotential hematopoietic precursors 总被引:3,自引:1,他引:2
Marrow cells from 5-fluorouracil (5-FU)-treated mice formed few or no mixed erythroid colonies when plated in semisolid medium with interleukin 3 (IL 3) and erythropoietin (Ep) alone. When conditioned medium (CM) from plastic-adherent marrow or thymus cells was also included, however, growth of mixed erythroid colonies was strongly stimulated. Both IL 3 and the accessory activity (AA) had to be present at the initiation of the cultures for growth to occur. AA was also produced by a cloned immortalized line (95/1.7) of fibroblastoid marrow cells that lacked macrophage-specific cell surface markers. Colony- stimulating factor-1 (CSF-1) was also released, but not granulocyte colony-stimulating activity. When 95/1.7 CM was analyzed by gel filtration, AA eluted with an apparent size of 35 kd and separated completely from the CSF-1. Biologic assays failed to detect IL 1 or IL 3 activity in 95/1.7 CM. Growth of mixed erythroid colonies from 5-FU- treated marrow is thus stimulated by adherent marrow cell-derived factors that appear distinct not only from the known CSFs including IL 3, but also from IL 1. 相似文献
84.
Serum vascular endothelial growth factor concentrations and ovarian stromal blood flow are increased in women with polycystic ovaries 总被引:4,自引:8,他引:4
Agrawal R; Sladkevicius P; Engmann L; Conway GS; Payne NN; Bekis J; Tan SL; Campbell S; Jacobs HS 《Human reproduction (Oxford, England)》1998,13(3):651-655
The aim of this study was to determine basal serum vascular endothelial
growth factor (VEGF) concentrations and Doppler blood flow changes within
the ovarian stroma of women with polycystic ovaries (PCO) and women with
normal ovaries. Pulsed and colour Doppler blood flows within the ovarian
stroma were recorded, and serum VEGF concentrations measured, in the early
follicular phase (days 2-3 of a menstrual cycle) in 60 women undergoing
ovarian stimulation for in-vitro fertilization. 36 women had normal
ovaries, 14 women had PCO as seen on pelvic ultrasound examination and 10
had polycystic ovarian syndrome (PCOS). Mean+/-SD serum VEGF concentrations
were significantly higher (P < 0.001) in women with PCO and PCOS
(3.4+/-0.7 and 3.2+/-0.66 ng/ml respectively) compared with women with
normal ovaries (2.3+/-0.5 ng/ml). Mean peak systolic blood flow velocity
(PSV) and time-averaged maximum flow velocity (TAMXV) were significantly
higher (P < 0.001) in women with PCO and PCOS compared with women with
normal ovaries. The mean PSV were 15+/-4 and 16+/-4 cm/s in women with PCO
and PCOS respectively, compared with 9+/-2 cm/s in women with normal
ovaries. The TAMXV were 9+/-3 and 11+/-3 cm/s in women with PCO and PCOS
respectively compared with women with normal ovaries (5.8+/-1.5 cm/s).
Serum VEGF concentrations were positively correlated with PSV (r=0.44,
P=0.001) and TAMXV (r=0.45, P < 0.000) in all three groups of women.
Higher serum concentrations of VEGF in women with PCO and PCOS may relate
to the increased vascularity that underlies the increased blood flow
demonstrated by Doppler blood flow velocity measurements in these women.
The results may explain the higher risk of ovarian hyperstimulation
syndrome in programmes of ovarian stimulation in patients with PCO compared
with those with normal ovaries.
相似文献
85.
美国口腔医学院的社区教学模式 总被引:1,自引:0,他引:1
高昂的医疗费用和不够便利的就医条件是阻碍美国人,特别是少数民族和劣势群体,获得口腔医疗护理的重要原因,其根源在于传统口腔教学僵化的教学方式和昂贵的学习费用.近年来,美国各界为改变口腔医疗的状况,进行了多种尝试,旨在降低口腔医学学习成本,并培养乐于奉献、积极投身社区医疗的口腔医师.该文分析了美同口腔医疗面临的问题及其原因,并以亚利桑那大学齿科与口腔健康学院的教学改革为例,介绍美国口腔医学教学如何与社区医疗相结合. 相似文献
86.
87.
地龙(蚯蚓)体内磷脂的组成和血小板活化因子的生物合成 总被引:4,自引:0,他引:4
首次发现低等动物地龙(Eisenia foetida,亦称蝗蚓)体内含有血小板活化因子(PAF),含量随季节变化,平均达10.7±6.1pmol/g湿重(或1.1±0.5μmol/mol磷脂)。磷脂成分中,PAF前体物质1-O-烷基-2-酰基(长链)-sn-甘油-3-磷酸胆碱占磷脂酰胆碱的比例高达61.4%。并证实地龙体内含有与哺乳类动物相同的两种PAF合成酶蛋白。当针刺、切断等伤害性刺激时,PAF水平显著升高。此结果提示PAF是一种初始的活性介质,在地龙这类低等动物体内也参与机体的病理、生理应急反应。本研究为阐明中药地龙的降血压等药理作用机理提供新线索。 相似文献
88.
The sulfide metabolite of sulindac prevents tumors and restores enterocyte apoptosis in a murine model of familial adenomatous polyposis 总被引:16,自引:5,他引:11
Mahmoud NN; Boolbol SK; Dannenberg AJ; Mestre JR; Bilinski RT; Martucci C; Newmark HL; Chadburn A; Bertagnolli MM 《Carcinogenesis》1998,19(1):87-91
Sulindac, a non-steroidal anti-inflammatory drug (NSAID), is effective in
treating intestinal adenomas in humans with Familial Adenomatous Polyposis
(FAP) and in preventing intestinal tumors in the C57Bl/6J- Min+ (Min)
mouse, an animal model of FAP. Sulindac is a prodrug metabolized by the
liver and intestinal flora to a sulfone, which has no anti-inflammatory
activity, and a sulfide, which is the active anti- inflammatory metabolite.
In this study, we determined which of these metabolites is responsible for
the anti-tumor effect of sulindac in Min mice. Min mice were treated with
either sulindac sulfone or sulindac sulfide (0.5 +/- 0.1 mg/day). Min mice
and homozygous C57Bl/6J-(+/+) normal litter-mates lacking the Apc mutation
(+/+) were used as controls. At 110 days of age, all mice were euthanized
and their intestinal tracts examined. Control Min mice had 33.2 +/- 6.6
tumors per mouse compared to 0.6 +/- 0.3 tumors for sulindac
sulfide-treated Min mice (P < 0.001) and 21.9 +/- 4.5 tumors per mouse
for sulindac sulfone-treated Min mice (P > 0.05). Decreased enterocyte
apoptosis was observed in Min control mice and Min mice treated with
sulindac sulfone. Sulindac sulfide restored to normal the level of
apoptosis in the mucosa of Min animals and decreased levels of PGE2 in the
small intestine of treated Min animals by 59% (P < 0.001). These data
suggest that the anti-tumor effect of sulindac in Apc-deficient animals is
mediated by the sulfide metabolite and correlates with suppression of
tissue prostaglandin synthesis.
相似文献
89.
van Leth F Conway B Laplumé H Martin D Fisher M Jelaska A Wit FW Lange JM;NN study group 《Antiviral therapy》2004,9(5):721-728
OBJECTIVE: To assess whether differences in safety profiles between nevirapine (NVP) and efavirenz (EFV), as observed in the 2NN study, translated into differences in 'health related quality of life' (HRQoL). DESIGN: A sub-study of the 2NN study, with antiretroviral-naive patients randomly allocated to NVP (once or twice daily), EFV or NVP+EFV, in addition to stavudine and lamivudine. METHODS: Comparing differences in changes of HRQoL over 48 weeks as measured with the Medical Outcomes Study HIV Health Survey (MOS-HIV) questionnaire, using analysis of variance. RESULTS: The 2NN study enrolled 1216 patients. No validated questionnaires were available for 244 patients, and 55 patients had no HRQoL data at all, leaving 917 patients eligible for this sub-study. A total of 471 (51%) had HRQoL measurements both at baseline and week 48. The majority (69%) of patients without HRQoL measurements did, however, complete the study. The change in the physical health score (PHS) was 3.9 for NVP, 3.4 for EFV and 2.4 for NVP+EFV (P=0.712). For the mental health score (MHS) these values were 6.1, 7.0 and 3.9, respectively (P=0.098). A baseline plasma HIV-1 RNA concentration (pVL) > or = 100,000 copies/ml and a decline in pVL (per log10) were independently associated with an increase of PHS. An increase of MHS was only associated with pVL decline. Patients experiencing an adverse event during follow-up had a comparable change in PHS but a significantly smaller change in MHS, compared with those without an adverse event. CONCLUSIONS: First-line ART containing NVP and/or EFV leads to an improvement in HRQoL. The gain in HRQoL was similar for NVP and EFV, but slightly lower for the combination of these drugs. 相似文献
90.
Kappelhoff BS van Leth F MacGregor TR Lange J Beijnen JH Huitema AD;NN Study Group 《Antiviral therapy》2005,10(1):145-155
OBJECTIVE: The aim of this 2NN pharmacokinetic substudy was to investigate the population pharmacokinetics of nevirapine and efavirenz. METHODS: Treatment-naive, HIV-1-infected patients received nevirapine (once or twice daily), efavirenz or a combination with lamivudine and stavudine. Blood samples were collected on day 3 and weeks 1, 2, 4, 24 and 48. Using non-linear mixed effects modelling, pharmacokinetics of nevirapine and efavirenz and factors involved in the inter-individual variability were investigated. RESULTS: Clearance of nevirapine in the induction phase (<14 days) and at steady state (>28 days) were 2.02 I/h and 2.81 I/h, respectively. Volume of distribution and absorption rate constant were 77.0 l and 1.66 h(-1), respectively. Clearance of nevirapine was lower in females (13.8%) and in patients with hepatitis B (19.5%). Patients from South America and Western countries had higher clearance of nevirapine compared with Thai and South African patients. The clearances of efavirenz in the induction phase and at steady state were 7.95 l/h and 8.82 l/h, respectively. The volume of distribution and absorption rate constant were 4181 and 0.287 h(-1), respectively. Concomitant use of nevirapine increased clearance of efavirenz (43%). Patients from Thailand had lower clearance than the rest of the population. CONCLUSIONS: The population pharmacokinetics of nevirapine and efavirenz were assessed in the 2NN trial. For both drugs, an induction phase was distinguished from the steady-state phase. Gender, hepatitis B and geographical region were involved in the variability of the pharmacokinetics of nevirapine. Region and concomitantly used nevirapine were determinants of the pharmacokinetics of efavirenz. 相似文献